Eficacia y seguridad de eltrombopag como agente trombopoyético para el tratamiento de la púrpura trombocitopénica inmune en pacientes que iniciaron tratamiento en el Complejo Asistencial Universitario de León en el periodo 2012-2015

  1. GÓMEZ, Pedro 1
  2. GONZÁLEZ, María Asunción 1
  3. MARTÍN, Aníbal 1
  4. ORTIZ DE URBINA, Juan José 2
  1. 1 Complejo Asistencial Universitario de León. Farmacia Hospitalaria
  2. 2 Complejo Asistencial Universitario de León
    info

    Complejo Asistencial Universitario de León

    León, España

    ROR https://ror.org/05gn84d31

Journal:
Farmajournal

ISSN: 2445-1355

Year of publication: 2017

Volume: 2

Issue: 2

Pages: 59-67

Type: Article

DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Farmajournal

Abstract

Immune thrombocytopenic purpura (ITP) is an autoinmune chronic disease that can lead to platelet count under 100.000/?L. Patients may develop purpuric lesions with possible hemorrhagic events. The diagnosis is made by exclusion and the treatment target is to obtain a platelet count superior to 100.000/?L.                                                                                                                                       Eltrombopag is an oral thrombopoietin receptor agonist, indicated for the second-line pharmacological treatment in splenectomized patients with chronic ITP and refractoriness to other treatments.                                                                                   The objetive of this study is to determine the efficacy and safety of the treatment. For this purpose, the dispensation registry and clinical histories of the treated patients during the period of 2012-2015 from Complejo Asistencial Universitario de León were revised.                                                                             Once the data was compiled and meticulously analysed, it can be concluded that: Most of the studied patients were able to reach the therapeutic target even though the platelet evolution didn't follow a linear progression, and the principal cause of suspension of the treatment was due to weak side effects

Bibliographic References

  • Cines BD, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106:2244-2251.
  • González-López, T.J, Pascual C, Álvarez-Román, M.T. et al. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia. Am J Hematol. 2015; 90:E40–E43.
  • Jarque I, Sanz MA. Trombocitopenia inmune primaria. Rovira M, Sanz J. Manual práctico de hematología clínica. 5ª ed. España: Editorial Antares. 2015 p.467-472.
  • Lab Novartis Europharm Limited. Ficha técnica de Revolade®. ® [actualizado en abril de 2010]. Disponible en: http://www.aemps.es/.
  • Lozano M L, Vicente V. Tratamiento de la trombocitopenia inmune primaria. Med Clin (Barc), 2014, vol. 142, no 9, p. 399-405.
  • Provan D. Characteristics of immune thrombocytopenic purpura: a guide for clinical practice. Eur J Haematol Suppl 2009; 82:8 – 12.
  • Saleh MN, Bussel JB, Cheng G, et al. EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121(3):537-545.
  • Sanz MA, Vicente V, Fernández A, López MF, Grande C, Jarque I. Diagnóstico, tratamiento y seguimiento de la trombocitopenia inmune primaria. Med Clin (Barc), 138 (2012), pp. 261.e1-261.e17
Data source: Dialnet